Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Verici DxVRCDF -60.53% 3-Year Share Buyback Ratio is -107.10 as of Dec. 2025. The stock has 3 warning signs investors should review. Among 173 Medical Diagnostics & Research companies, Verici Dx ranks worse than 94.8% on this metric.
Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.
3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. Verici Dx's current 3-Year Share Buyback Ratio was -107.10%.
The historical rank and industry rank for Verici Dx's 3-Year Share Buyback Ratio or its related term are showing as below:
VRCDF'
s 3-Year Share Buyback Ratio Range Over the Past 10 Years
Min: -107.1 Med: -19.6 Max: -6.3
Current: -107.1
During the past 6 years, Verici Dx's highest 3-Year Share Buyback Ratio was -6.30%. The lowest was -107.10%. And the median was -19.60%.
VRCDF's 3-Year Share Buyback Ratio is ranked worse than 94.8% of 173
companies
in the Medical Diagnostics & Research industry
Industry Median: -2.4
vs VRCDF: -107.10
Verici Dx (OTCPK:VRCDF) 3-Year Share Buyback Ratio Explanation
A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.
Be Aware
Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.
Verici Dx 3-Year Share Buyback Ratio Related Terms
VRCDF vs TMO, DHR, IDXX: 3-Year Share Buyback Ratio Comparison
For the Diagnostics & Research subindustry, Verici Dx's 3-Year Share Buyback Ratio, along with its competitors' market caps and 3-Year Share Buyback Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Verici Dx 3-Year Share Buyback Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Verici Dx's 3-Year Share Buyback Ratio distribution charts can be found below:
* The bar in red indicates where Verici Dx's 3-Year Share Buyback Ratio falls into.
This is the annualized percentage change in shares outstanding from three years ago to the current year. The annualized percentage change is calculated with expontential compound based on the latest four years of annual data on Shares Outstanding (EOP).
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
What does a 3-Year Share Buyback Ratio of -107.10 mean?
Verici Dx (VRCDF) has a 3-Year Share Buyback Ratio of -107.10 as of Dec. 2025. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for Verici Dx and its competitors. According to the industry distribution chart, Verici Dx ranks #164 out of 173 companies in the Medical Diagnostics & Research industry, placing it in the top 94.8%.
Is Verici Dx's 3-Year Share Buyback Ratio too high?
Verici Dx's current 3-Year Share Buyback Ratio is -107.10. Based on the distribution chart, Verici Dx ranks #164 out of 173 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers.
How does Verici Dx's 3-Year Share Buyback Ratio compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Verici Dx ranks #164 out of 173 companies for 3-Year Share Buyback Ratio. This places Verici Dx in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Share Buyback Ratio for a Medical Diagnostics & Research company?
A good 3-Year Share Buyback Ratio depends on the Medical Diagnostics & Research industry context. However, 3-Year Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Share Buyback Ratio mean?
A high 3-Year Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for Verici Dx and its competitors. Verici Dx's current 3-Year Share Buyback Ratio is -107.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Verici Dx stock overvalued right now?
Verici Dx (VRCDF) has a current 3-Year Share Buyback Ratio of -107.10. The current 3-Year Share Buyback Ratio is -107.10. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Share Buyback Ratio calculated?
3-Year Share Buyback Ratio is calculated from a company's financial statements. For Verici Dx (VRCDF), the current 3-Year Share Buyback Ratio is -107.10 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Verici Dx PLC is an immuno-diagnostics development company. The company is focused on the development of prognostic and diagnostic tests for kidney transplant patients. There are two products for clinical validation and commercialization: Clarava, which is a pre-transplant prognosis for the risk of early acute rejection; Tuteva, a post-transplant diagnostic focused upon acute cellular rejection, including sub-clinical rejection not being diagnosed through the current standard of care of rising serum creatine levels; and Protega will utilize RNA gene signatures to more accurately risk stratify outcome from fibrosis in a transplant patient. The business of the Group comprises a single activity, which of the development of prognostic and diagnostic tests for kidney transplant patients.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VRCDF has been successfully added to your 
